Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
ApexOnco Front Page
Recent articles
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
A second global pivotal trial will test iza-bren in the same NSCLC setting where patri-dxd failed.
The speciality pharma will gain the approved Danyelza and a radiopharma pipeline.
A phase 2 trial of the Car-T project BNT211 is withdrawn just months after it began.
The company gets another odronextamab knockback, while a key fianlimab readout is postponed.
The move comes after a death in the Alpha-3 cema-cel study.
Approvals come for Regeneron and Dizal, but Roche and Replimune see knockbacks.
